BLOOMINGTON, INDIANA-April 17, 2009-BioConvergence, a Bloomington, Indianabased contract solutions provider to the biotech and pharmaceutical industries, celebrates its 3rd year of operations in the life sciences industry. Recent accomplishments include:
-Retaining 99% of its more than 100 clients, including 10% from the State of Indiana and 10% from outside the United States
-Attracting more than 40 life sciences professionals and expanding facilities to serve more clients
-Adding new clinical manufacturing, packaging and QC testing services to complement its existing core of product development and supply chain
management services
-Consistently increasing revenue by providing the functions that enable clients to reach the clinic faster at reduced costs
-Leveraging the strengths of clients, employees and board members to become a collaborative partner for companies adopting the Fully Integrated Pharmaceutical Network, or FIPnet, drug development model
“We are blessed to be celebrating this special day,” said Alisa Wright, CEO and founder of BioConvergence. “At a time when challenging economic conditions have changed the game for virtually all businesses and industries, we are grateful our clients continue to trust us to develop their life-saving products.”
About BioConvergence LLC
BioConvergence is a leading contract solutions provider for the biotech and pharmaceutical industries. We offer the following services for our global client base: product development, cGMP supply chain & materials management, toxicology and clinical materials manufacturing & packaging, QC testing and consulting services. BioConvergence is the first solutions provider to offer its secure E-Transparency Solution enabling clients to access their data 24/7. BioConvergence is a women-owned, small business based in Bloomington, Indiana. For more information, visit us at www.bioc.us.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.